Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Syndax Pharmaceuticals
Pharma
Syndax ends IPF development after phase 2 disappointment
In topline phase 2 results, Syndax’s Niktimvo did not slow worsening lung function in IPF patients compared to placebo.
Donavyn Coffey
Oct 13, 2026 11:25am
Kyowa Kirin, Kura snag FDA nod for oral AML drug Komzifti
Nov 13, 2025 11:53am
For 2nd time in three months, Syndax wins FDA nod for a new drug
Nov 18, 2024 11:09am
Syndax strikes $350M funding deal with Royalty Pharma
Nov 5, 2024 10:50am
